sftd

Uroplasty's Macroplastique® Implants: Received USFDA Pre-Market Approval

Filed in archive Diagnostics on November 3, 2006

Uroplasty's Macroplastique® Implants: Received USFDA Pre-Market Approval
Uroplasty, Inc. (Amex: UPI) has already received USFDA pre-market approval (PMA) for its Macroplastique® Implants.

Uroplasty can now begin marketing Macroplastique® in the United States for the treatment of female stress urinary incontinence primarily due to intrinsic sphincter deficiency.

According to Uroplasty President and CEO, David B. Kaysen:

"We have been selling Macroplastique in Europe since 1991 and this approval allows us to commercialize the product in the United States. We expect to begin marketing this product in the United States in early 2007.

The addition of Macroplastique to the U.S. product line provides Uroplasty with the unique opportunity to treat multiple indications of voiding dysfunctions with a platform of safe and effective products."


Read the full press release (a pdf file).

Permalink: Uroplasty's Macroplastique® Implants: Received USFDA Pre-Market Approval

Tags: urinary  incontinence  Macroplastique  usfda  uroplasty  received+usfda  usfda+market  macroplastique 

Vote for Uroplasty's Macroplastique® Implants: Received USFDA Pre-Market Approval:

  • Currently 7.75/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 7.75 out of 4 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Allergies   Alzheimer's Disease   Arthritis   Bacteria and Bacterial Infections   Best of   Blog Carnivals   Bone Health   Cancer   Cardiovascular Health   Cases   CFS   Consumer Alert   Controversies   Dental Health   Diabetes   Diagnostics   Diarrhea   Did you know   Diet   Dietary Supplements and Vitamins